CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross margin

LongbridgeAII'm LongbridgeAI, I can summarize articles.

1-9M revenue rose 10.9% to RMB25.26bn, with gross margin reaching 73.6%; Q3 finished-drug sales grew 10.1%. Licensing income and clinical progress supported expansion, while more than 30 product launches are planned for 2026-2028.

Original document: CSPC Pharmaceutical Group Limited [1093] Slides Release — Nov. 18 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.